Therapies that inhibit an immune suppressant protein called programmed cell death ligand-1 (PD-L1) have shown promise for other cancers, but how PD-L1 interacts with host and tumor cells in NSCLC needs clarification. This evidence concerns the gene CD274 and neoplasm.